Boehringer Ingelheim, Evotec and Bio Mérieux Establish Joint Venture to Combat Antibiotic Resistance

Fight against AMR Boehringer Ingelheim, Evotec and Bio Mérieux Establish Joint Venture to Combat Antibiotic Resistance

2022-07-07 Source: Press release MA Alexander Stark

Biopharmaceutical company Boehringer Ingelheim, together with Evotec and Bio Mérieux, announced the creation of a joint venture. Aurobac will develop the next generation of antimicrobial agents and diagnostics to combat antimicrobial resistance.

Aurobac will work on changing the antibiotic treatment strategy.(Source: Boehringer Ingelheim) — Aurobac will work on changing the antibiotic treatment strategy.
(Source: Boehringer Ingelheim)

The newly formed company, Aurobac Therapeutics, combines the core competencies of the three founding companies Boehringer Ingelheim, Evotec and Bio Mérieux. The joint venture's mission is to develop a new approach to precision medicine from diagnosis to cure. The aim is to take up the fight against antimicrobial resistance (AMR), which is a massive health threat.

Aurobac will therefore work to change the strategy of antibiotic treatment, which currently relies heavily on empirical approaches using broad-spectrum and non-focused drugs. This will be transformed into a precision approach using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to rapidly identify pathogens and their resistance patterns, and supported by new economic models.

The 41-million-dollar joint venture, based in Lyon, France, is funded by Boehringer Ingelheim as lead investor with 31 million dollars from Evotec and Bio Mérieux with five million euros each and combines the expertise of Evotec, one of the most active research companies in infectious diseases, with Bio Mérieux's know-how in infectious disease diagnostics and with Boehringer Ingelheim's significant clinical development capabilities.

Boehringer Ingelheim's investment in Aurobac is part of a broader so-called pandemic preparedness initiative, which includes a 51-million-dollar investment in Boehringer Ingelheim's AMR Action Fund. The Boehringer Ingelheim Venture Fund has committed to invest up to twelve million euros in companies working on AMR infections.

(ID:48459067)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.